Timobesone is a topical corticosteroid and thiol ester derivative with anti-inflammatory activity.

Trimoxamine hydrochloride is an antihypertensive agent.

Pfizer was developing UK-396,082, an imidazole-propionic acid, as an oral treatment for thrombosis and pulmonary fibrosis. UK-396,082 is a potent and selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (activated TAFI; TAFIa) with Ki of 10 nM. UK-396,082 displays excellent selectivity over plasma carboxypeptidase N (>1,000-fold); exhibits antithrombotic efficacy in a rabbit model of venous thrombosis, yet has no effect on surgical bleeding in the rabbit; possesses excellent preclinical and clinical pharmacokinetic profile. UK-396,082 showed potential for the treatment of thrombosis and other fibrin-dependent diseases in humans, however its development was discontinued.

Streptoniazid is a streptomycin derivative patented by Societe des usines chimiques de Rhone-Poulenc as antibiotic effective against tuberculosis.

Mexrenoate potassium is an aldosterone antagonist, which was developed as an antihypertensive agent. However, this drug has never been marketed.

Oxifentorex was developed as a CNS stimulant and anorectic agent. However, information about the current use of this compound is not available.

Spiroxasone is a synthetic, steroidal antimineralocorticoid of the spirolactone group patented by Merck & Co., Inc. as a diuretic and antihypertensive agent. Spiroxasone acts as potent aldosterone antagonists in animals and humans.